A citation-based method for searching scientific literature

F Gasparini, K Lingenhöhl, N Stoehr, P J Flor, M Heinrich, I Vranesic, M Biollaz, H Allgeier, R Heckendorn, S Urwyler, M A Varney, E C Johnson, S D Hess, S P Rao, A I Sacaan, E M Santori, G Veliçelebi, R Kuhn. Neuropharmacology 1999
Times Cited: 644







List of co-cited articles
1214 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
34

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
Richard H P Porter, Georg Jaeschke, Will Spooren, Theresa M Ballard, Bernd Büttelmann, Sabine Kolczewski, Jens-Uwe Peters, Eric Prinssen, Jürgen Wichmann, Eric Vieira,[...]. J Pharmacol Exp Ther 2005
230
28

Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain.
Andrew S Doré, Krzysztof Okrasa, Jayesh C Patel, Maria Serrano-Vega, Kirstie Bennett, Robert M Cooke, James C Errey, Ali Jazayeri, Samir Khan, Ben Tehan,[...]. Nature 2014
289
23

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
Nicholas D P Cosford, Lida Tehrani, Jeffrey Roppe, Edwin Schweiger, Nicholas D Smith, Jeffrey Anderson, Linda Bristow, Jesse Brodkin, Xiaohui Jiang, Ian McDonald,[...]. J Med Chem 2003
291
23

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
21

Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator.
Huixian Wu, Chong Wang, Karen J Gregory, Gye Won Han, Hyekyung P Cho, Yan Xia, Colleen M Niswender, Vsevolod Katritch, Jens Meiler, Vadim Cherezov,[...]. Science 2014
361
17

AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
Ivo Vranesic, Silvio Ofner, Peter Josef Flor, Graeme Bilbe, Rochdi Bouhelal, Albert Enz, Sandrine Desrayaud, Kevin McAllister, Rainer Kuhn, Fabrizio Gasparini. Bioorg Med Chem 2014
36
47

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.
J C Pecknold, D J McClure, L Appeltauer, L Wrzesinski, T Allan. J Clin Psychopharmacol 1982
127
15

CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
S Litschig, F Gasparini, D Rueegg, N Stoehr, P J Flor, I Vranesic, L Prézeau, J P Pin, C Thomsen, R Kuhn. Mol Pharmacol 1999
282
15

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
414
14

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
Lothar Lindemann, Richard H Porter, Sebastian H Scharf, Basil Kuennecke, Andreas Bruns, Markus von Kienlin, Anthony C Harrison, Axel Paehler, Christoph Funk, Andreas Gloge,[...]. J Pharmacol Exp Ther 2015
70
20

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.
E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider, J Yuhas, J Hutchison, M Snape, M Tranfaglia, D V Nguyen,[...]. J Med Genet 2009
265
13

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lothar Lindemann, Georg Jaeschke, Aubin Michalon, Eric Vieira, Michael Honer, Will Spooren, Richard Porter, Thomas Hartung, Sabine Kolczewski, Bernd Büttelmann,[...]. J Pharmacol Exp Ther 2011
77
16

The mGluR theory of fragile X mental retardation.
Mark F Bear, Kimberly M Huber, Stephen T Warren. Trends Neurosci 2004
13

A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors.
Etienne Doumazane, Pauline Scholler, Jurriaan M Zwier, Eric Trinquet, Philippe Rondard, Jean-Philippe Pin. FASEB J 2011
198
12

A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
M J Noetzel, K J Gregory, P N Vinson, J T Manka, S R Stauffer, C W Lindsley, C M Niswender, Z Xiang, P J Conn. Mol Pharmacol 2013
64
18

Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.
Andrew S Felts, Alice L Rodriguez, Ryan D Morrison, Daryl F Venable, Jason T Manka, Brittney S Bates, Anna L Blobaum, Frank W Byers, J Scott Daniels, Colleen M Niswender,[...]. Bioorg Med Chem Lett 2013
26
46

Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.
Karen J Gregory, Elizabeth D Nguyen, Sean D Reiff, Emma F Squire, Shaun R Stauffer, Craig W Lindsley, Jens Meiler, P Jeffrey Conn. Mol Pharmacol 2013
60
20

Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.
N Kunishima, Y Shimada, Y Tsuji, T Sato, M Yamamoto, T Kumasaka, S Nakanishi, H Jingami, K Morikawa. Nature 2000
932
12

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
12

Structures of the extracellular regions of the group II/III metabotropic glutamate receptors.
Takanori Muto, Daisuke Tsuchiya, Kosuke Morikawa, Hisato Jingami. Proc Natl Acad Sci U S A 2007
265
12

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
Georg Jaeschke, Sabine Kolczewski, Will Spooren, Eric Vieira, Nadia Bitter-Stoll, Patrick Boissin, Edilio Borroni, Bernd Büttelmann, Simona Ceccarelli, Nicole Clemann,[...]. J Med Chem 2015
43
27

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Fabrizio Stocchi, Olivier Rascol, Alain Destee, Nobutaka Hattori, Robert A Hauser, Anthony E Lang, Werner Poewe, Mark Stacy, Eduardo Tolosa, Haitao Gao,[...]. Mov Disord 2013
100
12

Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
Alice L Rodriguez, Mark D Grier, Carrie K Jones, Elizabeth J Herman, Alexander S Kane, Randy L Smith, Richard Williams, Ya Zhou, Joy E Marlo, Emily L Days,[...]. Mol Pharmacol 2010
144
12

Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
John A Christopher, Sarah J Aves, Kirstie A Bennett, Andrew S Doré, James C Errey, Ali Jazayeri, Fiona H Marshall, Krzysztof Okrasa, Maria J Serrano-Vega, Benjamin G Tehan,[...]. J Med Chem 2015
104
12

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
François Tison, Charlotte Keywood, Mark Wakefield, Franck Durif, Jean-Christophe Corvol, Karla Eggert, Mark Lew, Stuart Isaacson, Erwan Bezard, Sonia-Maria Poli,[...]. Mov Disord 2016
82
14

Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain.
R Shigemoto, S Nomura, H Ohishi, H Sugihara, S Nakanishi, N Mizuno. Neurosci Lett 1993
452
11


Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
Karen J Gregory, Meredith J Noetzel, Jerri M Rook, Paige N Vinson, Shaun R Stauffer, Alice L Rodriguez, Kyle A Emmitte, Ya Zhou, Aspen C Chun, Andrew S Felts,[...]. Mol Pharmacol 2012
67
16

A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
Julie A O'Brien, Wei Lemaire, Tsing-Bau Chen, Raymond S L Chang, Marlene A Jacobson, Sookhee N Ha, Craig W Lindsley, Hervé J Schaffhauser, Cyrille Sur, Douglas J Pettibone,[...]. Mol Pharmacol 2003
186
11



JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.
Hilde Lavreysen, Ria Wouters, François Bischoff, Sandrina Nóbrega Pereira, Xavier Langlois, Saskia Blokland, Marijke Somers, Lieve Dillen, Anne S J Lesage. Neuropharmacology 2004
115
10

Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP.
Jesper Mosolff Mathiesen, Nannette Svendsen, Hans Bräuner-Osborne, Christian Thomsen, M Teresa Ramirez. Br J Pharmacol 2003
143
10


Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Aubin Michalon, Michael Sidorov, Theresa M Ballard, Laurence Ozmen, Will Spooren, Joseph G Wettstein, Georg Jaeschke, Mark F Bear, Lothar Lindemann. Neuron 2012
348
10

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5.
M A Varney, N D Cosford, C Jachec, S P Rao, A Sacaan, F F Lin, L Bleicher, E M Santori, P J Flor, H Allgeier,[...]. J Pharmacol Exp Ther 1999
174
10

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
Z A Hughes, S J Neal, D L Smith, S J Sukoff Rizzo, C M Pulicicchio, S Lotarski, S Lu, J M Dwyer, J Brennan, M Olsen,[...]. Neuropharmacology 2013
65
15

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
Sebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, Lothar Lindemann. Curr Opin Pharmacol 2015
69
14

Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.
Simon M Ametamey, Valerie Treyer, Johannes Streffer, Matthias T Wyss, Mark Schmidt, Milen Blagoev, Samuel Hintermann, Yves Auberson, Fabrizio Gasparini, Uta C Fischer,[...]. J Nucl Med 2007
132
10

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Daniella Rylander, Hanna Iderberg, Qin Li, Andrzej Dekundy, Jinlan Zhang, Hao Li, Ren Baishen, Wojciech Danysz, Erwan Bezard, M Angela Cenci. Neurobiol Dis 2010
125
10

The metabotropic glutamate receptors: structure and functions.
J P Pin, R Duvoisin. Neuropharmacology 1995
10

Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.
Craig W Lindsley, Kyle A Emmitte, Corey R Hopkins, Thomas M Bridges, Karen J Gregory, Colleen M Niswender, P Jeffrey Conn. Chem Rev 2016
114
10

[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor.
Nicholas D P Cosford, Jeffrey Roppe, Lida Tehrani, Edwin J Schweiger, T Jon Seiders, Ashok Chaudary, Sara Rao, Mark A Varney. Bioorg Med Chem Lett 2003
113
9

Metabotropic glutamate receptors.
Francesco Ferraguti, Ryuichi Shigemoto. Cell Tissue Res 2006
355
9

Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.
Alexis S Hammond, Alice L Rodriguez, Steven D Townsend, Colleen M Niswender, Karen J Gregory, Craig W Lindsley, P Jeffrey Conn. ACS Chem Neurosci 2010
58
15

Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.
F Knoflach, V Mutel, S Jolidon, J N Kew, P Malherbe, E Vieira, J Wichmann, J A Kemp. Proc Natl Acad Sci U S A 2001
196
9



Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling.
Andrew C Emery, John O DiRaddo, Eric Miller, Hannah A Hathaway, Sergey Pshenichkin, Guy Rodrigue Takoudjou, Ewa Grajkowska, Robert P Yasuda, Barry B Wolfe, Jarda T Wroblewski. Mol Pharmacol 2012
37
24


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.